WELCOME TO
Hydra ENT
An Advanced Medical Device Company
Our Technology
SPARx is a first-in-class sinuplasty platform that combines electricity with an FDA approved drug.
This product will revolutionize ENT medicine by offering maximum relief without side effects. SPARx carries less drug, and takes only seconds to securely localize to it's target tissue. The result is a better quality of life and less maintenance.
Making Mometasone Furoate (MF, the active drug in Nasonex) last up to 30 days from one maximum dose!
​
Imagine going to one short visit with your doctor, and leaving free of sinus issues, prescriptions or maintenance protocols.
​
SinuSPARx, is an FDA approval away from giving you relief. Our preclinical data shows that from a one-day dose equivalent of Nasonex, inflammation is suppressed for 30-40 days. That's 30x less MF for you to put in you body over a 30 day period! Your pancreas, liver, and kidneys will thank you for the SinuSPARx treatment.
Investment opportunity
VALUATION: $25M Post Money
​
Seed Round: $5M​
​
Accepting Convertible Notes:
-
Please contact us for details
HydraENT is poised to rebound from a missed investment of $3 million following the SVB collapse. We are actively seeking new investors and strategic partners to reignite our momentum and drive our vision forward. Join us as we explore exciting opportunities for growth and innovation in the evolving landscape. Together, we can achieve remarkable success.
